Upadacitinib's Real-World Impact on Atopic Dermatitis: A 2-Year Study
A new drug, upadacitinib, has been making waves in the treatment of severe eczema, also known as atopic dermatitis (AD). This medication is a Janus kinase (JAK) inhibitor, which means it stops certain enzymes from causing inflammation. It's been approved for kids aged 12 and above who have moderate